Selectivity Profiling of the Novel EP2 Receptor Antagonist, PF-04418948, in Functional Bioassay Systems: Atypical Affinity at the Guinea Pig EP2 Receptor

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2012 Jul 4

PMID 22747912

Citations 16

Authors

Mark A Birrell

Sarah A Maher

James Buckley

Nicole Dale

Sara Bonvini

Kristof Raemdonck

Nick Pullen

Mark A Giembycz

Maria G Belvisi

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Understanding the role of the EP(2) receptor has been hampered by the lack of a selective antagonist. Recently, a selective EP(2) receptor antagonist, PF-04418948, has been discovered. The aim of this study was to demonstrate the selectivity profile of PF-04418948 for the EP(2) receptor over other EP receptors using a range of isolated tissue systems.

Experimental Approach: PF-04418948 was profiled on a range of isolated tissues to assess its EP receptor potency and selectivity: ONO-DI-004-induced contraction of guinea pig trachea (EP(1)); ONO-AE1-259 and PGE(2)- induced relaxation of mouse and guinea pig trachea (EP(2)); PGE(2)-induced depolarization of guinea pig isolated vagus (EP(3)); PGE(2)-induced relaxation of human and rat trachea (EP(4)). PF-04418948 was also profiled in functional murine TP, IP, DP and FP receptor assays.

Key Results: In bioassay systems, where assessment of potency/selectivity is made against the 'native' receptor, PF-04418948 only acted as an antagonist of EP(2) receptor-mediated events. PF-04418948 competitively inhibited relaxations of murine and guinea pig trachea induced by ONO-AE1-259 and PGE(2) respectively. However, the affinity of PF-04418948 was not equal in the two preparations.

Conclusions And Implications: Using a wide range of bioassay systems, we have demonstrated that PF-04418948 is a selective EP(2)-receptor antagonist. Interestingly, an atypically low affinity was found on the guinea pig trachea, questioning its utility as an EP(2) receptor assay system. Nevertheless, this compound should be an invaluable tool for investigating the biological activity of PGE(2) and the role of EP(2) receptors in health and disease.

Citing Articles

Lipopolysaccharide-mediated effects of the microbiota on sleep and body temperature.

Szentirmai E, Buckley K, Massie A, Kapas L Sci Rep. 2024; 14(1):27378.

PMID: 39521828 PMC: 11550806. DOI: 10.1038/s41598-024-78431-1.

Platelet-derived growth factor (PDGF)-BB regulates the airway tone via activation of MAP2K, thromboxane, actin polymerisation and Ca-sensitisation.

Rieg A, Suleiman S, Anker C, Bunting N, Verjans E, Spillner J Respir Res. 2022; 23(1):189.

PMID: 35841089 PMC: 9287894. DOI: 10.1186/s12931-022-02101-x.

Single-cell analysis of prostaglandin E2-induced human decidual cell in vitro differentiation: a minimal ancestral deciduogenic signal†.

Stadtmauer D, Wagner G Biol Reprod. 2021; 106(1):155-172.

PMID: 34591094 PMC: 8757638. DOI: 10.1093/biolre/ioab183.

Ouabain Enhances Gap Junctional Intercellular Communication by Inducing Paracrine Secretion of Prostaglandin E2.

Ogazon Del Toro A, Jimenez L, Serrano Rubi M, Cereijido M, Ponce A Int J Mol Sci. 2021; 22(12).

PMID: 34200582 PMC: 8230150. DOI: 10.3390/ijms22126244.

Can GPCRs Be Targeted to Control Inflammation in Asthma?.

Sharma P, Penn R Adv Exp Med Biol. 2021; 1304:1-20.

PMID: 34019260 PMC: 8630641. DOI: 10.1007/978-3-030-68748-9_1.

References

Neubig R, Spedding M, Kenakin T, Christopoulos A . International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003; 55(4):597-606. DOI: 10.1124/pr.55.4.4. View

Sheller J, Mitchell D, Meyrick B, Oates J, Breyer R . EP(2) receptor mediates bronchodilation by PGE(2) in mice. J Appl Physiol (1985). 2000; 88(6):2214-8. DOI: 10.1152/jappl.2000.88.6.2214. View

Coleman R, Kennedy I . Characterisation of the prostanoid receptors mediating contraction of guinea-pig isolated trachea. Prostaglandins. 1985; 29(3):363-75. DOI: 10.1016/0090-6980(85)90096-6. View

Henry P, Goldie R . Beta 1-adrenoceptors mediate smooth muscle relaxation in mouse isolated trachea. Br J Pharmacol. 1990; 99(1):131-5. PMC: 1917490. DOI: 10.1111/j.1476-5381.1990.tb14666.x. View

Jones R, Giembycz M, Woodward D . Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009; 158(1):104-45. PMC: 2795261. DOI: 10.1111/j.1476-5381.2009.00317.x. View

Lydford S, McKechnie K . Characterization of the prostaglandin E2 sensitive (EP)-receptor in the rat isolated trachea. Br J Pharmacol. 1994; 112(1):133-6. PMC: 1910312. DOI: 10.1111/j.1476-5381.1994.tb13042.x. View

Maher S, Birrell M, Belvisi M . Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Am J Respir Crit Care Med. 2009; 180(10):923-8. PMC: 2778154. DOI: 10.1164/rccm.200903-0388OC. View

Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F . The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000; 141(4):1554-9. DOI: 10.1210/endo.141.4.7405. View

McKenniff M, Rodger I, Norman P, Gardiner P . Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways. Eur J Pharmacol. 1988; 153(2-3):149-59. DOI: 10.1016/0014-2999(88)90601-2. View

10.

WAUD D, Son S, Waud B . Kinetic and empirical analysis of dose-response curves illustrated with a cardiac example. Life Sci. 1978; 22(13-15):1275-85. DOI: 10.1016/0024-3205(78)90096-6. View

11.

Alexander S, Mathie A, Peters J . Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol. 2008; 153 Suppl 2:S1-209. PMC: 2275471. DOI: 10.1038/sj.bjp.0707746. View

12.

Fortner C, Breyer R, Paul R . EP2 receptors mediate airway relaxation to substance P, ATP, and PGE2. Am J Physiol Lung Cell Mol Physiol. 2001; 281(2):L469-74. DOI: 10.1152/ajplung.2001.281.2.L469. View

13.

SCHILD H . pAx and competitive drug antagonism. Br J Pharmacol Chemother. 1949; 4(3):277-80. PMC: 1509912. DOI: 10.1111/j.1476-5381.1949.tb00548.x. View

14.

Karim S, Sandler M, Williams E . Distribution of prostaglandins in human tissues. Br J Pharmacol Chemother. 1967; 31:340-4. PMC: 1557379. DOI: 10.1111/j.1476-5381.1967.tb02003.x. View

15.

Giblin G, Bit R, Brown S, Chaignot H, Chowdhury A, Chessell I . The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Bioorg Med Chem Lett. 2006; 17(2):385-9. DOI: 10.1016/j.bmcl.2006.10.041. View

16.

Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010; 160(7):1577-9. PMC: 2936830. DOI: 10.1111/j.1476-5381.2010.00872.x. View

17.

Ndukwu I, White S, Leff A, Mitchell R . EP1 receptor blockade attenuates both spontaneous tone and PGE2-elicited contraction in guinea pig trachealis. Am J Physiol. 1997; 273(3 Pt 1):L626-33. DOI: 10.1152/ajplung.1997.273.3.L626. View

18.

Gaddum J . Theories of drug antagonism. Pharmacol Rev. 1957; 9(2):211-8. View

19.

Birrell M, De Alba J, Catley M, Hardaker E, Wong S, Collins M . Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. J Immunol. 2008; 181(6):4265-71. DOI: 10.4049/jimmunol.181.6.4265. View

20.

Buckley J, Birrell M, Maher S, Nials A, Clarke D, Belvisi M . EP4 receptor as a new target for bronchodilator therapy. Thorax. 2011; 66(12):1029-35. PMC: 3221321. DOI: 10.1136/thx.2010.158568. View